查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046559

鋅指核酸酶技術市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭格局分類，2021-2031年

Zinc Finger Nuclease Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, by End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球鋅指核酸酶 (ZFN) 技術市場預計將從 2025 年的 10.5413 億美元大幅成長至 2031 年的 29.6074 億美元，複合年成長率高達 18.78%。

鋅指核酸酶（ZFNs）發揮著至關重要的作用，是推動這一成長的關鍵因素。 ZFNs是一種特殊設計的DNA結合蛋白質，可透過靶向雙鏈來實現精準的基因組編輯。遺傳疾病發生率的不斷上升以及治療方法研發中對精準基因操作的需求，是推動市場發展的主要動力。活躍的臨床活動進一步促進了這一擴張。美國基因與細胞治療學會（ASGCT）預測，到2025年，全球將進行超過3,200項臨床試驗，凸顯了人們對有效工具以應對複雜疾病的日益成長的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1,054,130,000 美元
市場規模：2031年 2,960,740,000 美元
複合年成長率：2026-2031年 18.78%
成長最快的細分市場 動物基因工程
最大的市場 北美洲

市場促進因素

全球鋅指核酸酶 (ZFN) 技術市場的主要驅動力是生物技術和製藥業研發投入的顯著成長。業界向精準醫療的轉型正在推動對利用基因組編輯技術的先進治療方法的巨額投資，這對於克服 ZFN 工程的技術複雜性以及資助關鍵的臨床試驗至關重要。再生醫學聯盟的報告也印證了這一強勁的融資環境，該報告預測，到 2025 年 1 月，細胞和基因療法的投資將達到 152 億美元，同比成長 30%，這將使企業能夠強化其 ZFN 平台並保持競爭力。此外，基因組研究領域的策略夥伴關係和合作正在透過共用專業知識和降低研發風險來加速市場擴張。由於客製化 ZFN 需要大量的資金和專業知識，規模較小的生物技術公司擴大與大型製藥企業合作。例如，Sangamo Therapeutics 於 2025 年 5 月從禮來公司獲得了 1,800 萬美元的許可費，用於其針對神經系統疾病的療法。除了此類合作關係外，到 2025 年初已有 30 多種細胞和基因療法獲得 FDA核准，這表明 ZFN 具有治療潛力，並確保了必要資源的分配。

市場挑戰

鋅指核酸酶 (ZFN) 市場成長的主要障礙在於其研發所需的大量投入。與較簡單的基因編輯系統不同，ZFN 需要針對每個特定的 DNA 標靶客製設計蛋白質基序，導致研發過程繁瑣且需要反覆迭代。這種複雜性顯著增加了臨床候選藥物檢驗所需的成本和時間，從而限制了其應用，使其僅限於資金雄厚的大型機構，並阻礙了缺乏足夠財力開展此類高要求工作流程的中小型生物技術公司。這種巨大的資源負擔直接影響了市場擴張，降低了 ZFN 在快速發展的行業中的競爭力，而該行業更重視可擴展性和速度。根據美國基因與細胞治療學會 (ASCT) 統計，2024 年第三季新增了 19 個創業資金籌措計畫。隨著投資者越來越青睞敏捷技術，ZFN 漫長的設計週期和高昂的營運成本使其處於明顯的劣勢，與更有效率的替代方案相比，導致其獲得的大量投資減少。

市場趨勢

ZFN設計領域的一項變革性趨勢是人工智慧和機器學習的融合。這有效地解決了手動客製化DNA結合域的技術難題。開發人員現在利用複雜的演算法來預測蛋白質-DNA相互作用，從而顯著加快了高特異性核酸酶的開發，使其擺脫了耗時的迭代篩檢，轉而採用計算精確的方法。廣島大學的研究支持了這項進展，該研究於2024年5月發表在《先進科學》（Advanced Science）雜誌上。研究報告稱，透過使用機器學習驅動的模組化組裝系統，ZFN的基因組編輯效率提高了5%，證實了計算模型在簡化功能性高效編輯工具的生產方面的潛力。同時，市場正在策略性地調整其關注點，旨在將ZFN的應用範圍從人類治療擴展到作物品種改良，從而拓展其在農業生物技術領域的應用。這種多元化發展得益於全球主要地區法規環境的不斷變化，為不含外源DNA的基因編輯產品創造了清晰的商業化路徑。這一監管方面的進展在東南亞尤為顯著。根據國際農業生物技術核准服務組織（ISAAA）2024年8月發布的報告，泰國農業部長於2024年7月簽署了一項法案，旨在對基因編輯生物進行認證。這為ZFN開發者向泰國（一個主要的稻米生產國）引入農業解決方案開闢了一條至關重要的途徑。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：鋅指核酸酶技術的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（動物基因工程、細胞株工程、植物性因工程）
    • 按最終用戶（生物技術和製藥公司、學術和研究機構、醫院和診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美鋅指核酸酶技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鋅指核酸酶技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區鋅指核酸酶技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲鋅指核酸酶技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲鋅指核酸酶技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球鋅指核酸酶技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Applied Biological Materials, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis, Inc.
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Horizon Discovery Group, PLC
  • Intellia Therapeutics
  • Merck KGaA
  • OriGene Technologies, Inc
  • Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17281

The global Zinc Finger Nuclease Technology Market is projected to expand significantly, from USD 1,054.13 Million in 2025 to USD 2,960.74 Million by 2031, demonstrating an impressive 18.78% compound annual growth rate. This growth is underpinned by the essential role of Zinc Finger Nucleases (ZFNs), which are specially engineered DNA-binding proteins capable of precise genome editing through targeted double-strand breaks. The increasing incidence of genetic disorders and the imperative for accurate genetic manipulation in developing therapies are key market drivers. This expansion is further supported by robust clinical activity, with over 3,200 trials globally in 2025, according to the American Society of Gene & Cell Therapy, underscoring the rising demand for effective tools to address complex medical conditions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1,054.13 Million
Market Size 2031USD 2,960.74 Million
CAGR 2026-203118.78%
Fastest Growing SegmentAnimal Genetic Engineering
Largest MarketNorth America

Market Driver

A major catalyst for the global Zinc Finger Nuclease Technology Market is the significant increase in biotechnology and pharmaceutical R&D expenditure. The industry's pivot towards precision medicine is driving substantial financial investment into advanced therapies utilizing genomic editing, crucial for navigating the technical complexities of ZFN engineering and funding essential clinical trials. This robust financial environment is evidenced by a 30% year-over-year growth in cell and gene therapy investments to $15.2 billion in January 2025, as reported by the Alliance for Regenerative Medicine, empowering firms to enhance ZFN platforms and maintain competitiveness. Furthermore, strategic partnerships and collaborations in genomic research are accelerating market expansion by sharing expertise and reducing development risks. Due to the high costs and specialized knowledge required for ZFN customization, smaller biotech companies are increasingly partnering with large pharmaceutical firms, as demonstrated by Sangamo Therapeutics receiving an $18 million license fee from Eli Lilly in May 2025 for neurological disease targets. Such alliances, coupled with over 30 FDA approvals for cell and gene therapies by early 2025, validate ZFNs' therapeutic promise and ensure necessary resource allocation.

Market Challenge

A significant impediment to the market growth of Zinc Finger Nucleases (ZFNs) is the extensive engineering effort they require. Unlike simpler gene-editing systems, ZFNs necessitate a custom design of protein motifs for each specific DNA target, leading to a labor-intensive and iterative development process. This complexity substantially increases the cost and time for validating clinical candidates, thereby limiting accessibility primarily to larger, well-funded organizations and hindering adoption by smaller biotechnology firms without the requisite financial capacity for such demanding workflows. This substantial resource burden directly impacts market expansion by diminishing ZFNs' competitive appeal in a fast-evolving industry that values scalability and speed. With investors increasingly favoring agile technologies-as seen with 19 new programs funded in startup financing in the third quarter of 2024, according to the American Society of Gene & Cell Therapy-the longer timelines and higher operational costs associated with ZFN design put the technology at a distinct disadvantage, reducing its allocation of crucial investment compared to more efficient alternatives.

Market Trends

A transformative trend for ZFN design is the integration of AI and Machine Learning, which is effectively addressing the technical challenges of manually customizing DNA-binding domains. Developers are now utilizing advanced algorithms to predict protein-DNA interactions, moving from time-consuming iterative screening to computationally precise methods that significantly accelerate the development of highly specific nucleases. This advance is supported by research, such as a May 2024 study from Hiroshima University in 'Advanced Science', which reported a 5% improvement in ZFN genome editing efficiency using machine learning-driven modular assembly systems, confirming the potential of computational models to streamline functional and efficient editing tool production. Concurrently, the market is strategically pivoting towards expanding ZFN applications in agricultural biotechnology, moving beyond human therapeutics to enhance crop varieties. This diversification is driven by an evolving regulatory environment in key global regions that is creating clear commercialization pathways for gene-edited products free of foreign DNA. This regulatory progress is exemplified in Southeast Asia, where, according to the International Service for the Acquisition of Agri-biotech Applications in August 2024, Thailand's Minister of Agriculture signed legislation in July 2024 to certify genome-edited organisms, thereby opening a crucial avenue for ZFN developers to introduce agricultural solutions in a significant rice-producing nation.

Key Market Players

  • Applied Biological Materials, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis, Inc.
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Horizon Discovery Group, PLC
  • Intellia Therapeutics
  • Merck KGaA
  • OriGene Technologies, Inc
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Zinc Finger Nuclease Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Zinc Finger Nuclease Technology Market, By Type

  • Animal Genetic Engineering
  • Cell Line Engineering
  • Plant Genetic Engineering

Zinc Finger Nuclease Technology Market, By End User

  • Biotechnology and Pharmaceutical Companies
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Others

Zinc Finger Nuclease Technology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Zinc Finger Nuclease Technology Market.

Available Customizations:

Global Zinc Finger Nuclease Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Zinc Finger Nuclease Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Animal Genetic Engineering, Cell Line Engineering, Plant Genetic Engineering)
    • 5.2.2. By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Zinc Finger Nuclease Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Zinc Finger Nuclease Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Zinc Finger Nuclease Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Zinc Finger Nuclease Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Zinc Finger Nuclease Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Zinc Finger Nuclease Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Zinc Finger Nuclease Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Zinc Finger Nuclease Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Zinc Finger Nuclease Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Zinc Finger Nuclease Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Zinc Finger Nuclease Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Zinc Finger Nuclease Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Zinc Finger Nuclease Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Zinc Finger Nuclease Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Zinc Finger Nuclease Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Zinc Finger Nuclease Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Zinc Finger Nuclease Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Zinc Finger Nuclease Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Zinc Finger Nuclease Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Zinc Finger Nuclease Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. South America Zinc Finger Nuclease Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Zinc Finger Nuclease Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Zinc Finger Nuclease Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Zinc Finger Nuclease Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Zinc Finger Nuclease Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Applied Biological Materials, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Caribou Biosciences, Inc.
  • 15.3. Cellectis, Inc.
  • 15.4. GenScript Biotech Corporation
  • 15.5. Gilead Sciences, Inc.
  • 15.6. Horizon Discovery Group, PLC
  • 15.7. Intellia Therapeutics
  • 15.8. Merck KGaA
  • 15.9. OriGene Technologies, Inc
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer